First Author: A.Hassan GERMANY
Co Author(s): A. Fricke R. Fulga G. Auffarth D. Breyer K. Klabe H. Kaymak
Back to previous
To investigate the efficiency and safety of fluocinolone acetonide intravitreal implant in eyes with persistent diabetic macular edema (DME) over a follow-up period up to 2 years.
Internationale Innovative Ophthalmochirurgie Düsseldorf, Germany; International Vision Correction Research Network, Germany
Main outcome measures included the changes in intraocular pressure (IOP), best-corrected visual acuity (BCVA) and central subfield thickness (CST) (Cirrus HD-OCT; Zeiss) from baseline at scheduled visits following injection.
In this retrospective study, 33 eyes of 22 patients, who underwent an injection of intravitreal fluocinolone acetonide implant for the treatment of persistent diffuse DME, were reviewed. Mean BCVA at baseline and at months 1, 8 and 18 were 0.38 ± 0.15, 0.24 ± 0.14, 0.21 ± 0.13 and 0.16 ± 0.06 LogMAR, respectively. The evaluation of CST had shown a continuous improvement of the diabetic macular edema. Mean CST at baseline and at month 1, 8 and 18 were 389 ± 100 μm, 304 ± 57 μm, 307 ± 47 μm and 285 ± 30 μm, respectively. 14% of treated eyes showed an increase in IOP of ≥10 mmHg from baseline and needed an antiglaucoma treatment.
The switch to a fluocinolone acetonide implant in patients with persistent DME offers the possibility of a permanent functional and anatomical improvement of the eyes. It can therefore be an advantage to treat selected patients (anxiety patients or cardiovascular risk disorders) with this alternative therapy option.